GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

This is a single-center, randomized, open-label clinical trial designed to evaluate the impact of low-dose olanzapine on weight loss, appetite, and nutritional outcomes in patients with gastric cancer receiving neoadjuvant chemotherapy. Eligible patients will be randomized to receive olanzapine 2.5 mg orally once daily (QD) in addition to standard neoadjuvant chemotherapy, beginning prior to initiation of chemotherapy and continuing until surgical resection. Patients will otherwise receive standard-of-care (SOC) oncologic treatment, with no alterations to chemotherapy regimens or surgical mana

Trial Details

NCT ID
NCT07581405
Phase
PHASE2
Sponsor
University of Illinois Chicago
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Neoadjuvant chemotherapy
  • Olanzapine
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Age ≥ 18 years of age at time of consent
  • Eastern Cooperative Oncology Group (ECOG) score of 0-2
  • Histologically confirmed gastric adenocarcinoma, documented by biopsy.
  • Planned to receive neoadjuvant chemotherapy followed by surgical resection, as determined by the treating oncologist.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →